2026-08-05T16:12:55Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/270442025-12-18T12:57:38Zcom_20.500.12105_19586com_20.500.12105_2202col_20.500.12105_19587
Repisalud author Bonanad-Lozano, Clara author García Blas, Sergio author Amat-Santos, Ignacio author Gonzalez-Manzanares, Rafael author Sanchís, Juan author López Otero, Diego author Nombela Franco, Luis author Gheorge, Livia author Sanz-Sánchez, Jorge author Baladrón Zorita, Carlos author Iñiguez Romo, Andrés author Muñoz García, Antonio Jesús author Vilalta, Victoria author Ojeda, Soledad author Veiga Fernández, Gabriela author Córdoba Soriano, Juan Gabriel author Cepas, Pedro author Sandín Rollán, Miriam author Ríos, Xacobe Flores author Palma-Carbajal, Ricardo author Martín Reyes, Roberto author Romaguera, Rafael author Avanzas, Pablo author Franco-Peláez, Juan A author Martín Moreiras, Javier author Gonzalez Juanatey, José Ramón author Tirado, Gabriela author Calle, German author Díez, José Luis author Santos-Martínez, Sandra author Domínguez Erquicia, Pablo author García, Erika Muños author Fernandez-Nofrerias, Eduard author López País, Javier author Gonzalo, Nieves author Barri, Alejandro Gutierrez author Asmarats, Lluis author López Pérez, Manuel author Domínguez Rodríguez, Luis Manuel author Cobo, Marta author González Bermúdez, Inmaculada author García Álvarez, Ana author García Pavía, Pablo author Fuster, Valentín author Ibáñez, Borja author Raposeiras-Roubín, Sergio 2025-12-16T10:32:25Z 2025-12-16T10:32:25Z 2025-10-14 J Am Coll Cardiol. 2025 Oct 14;86(15):1128-1138. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 41062227 https://hdl.handle.net/20.500.12105/27044 Patients with aortic stenosis who undergo transcatheter aortic valve implantation (TAVI) experience a great improvement in health status. Dapagliflozin has been shown to reduce death and heart failure (HF) in these patients. However, the impact of dapagliflozin on improving health status after TAVI is unknown. In this prespecified analysis of the DapaTAVI (Dapagliflozin After Transcatheter Aortic Valve Implantation) trial, we examined the effects of dapagliflozin on health status by using the Kansas City Cardiomyopathy Questionnaire (KCCQ). The DapaTAVI trial randomized patients undergoing TAVI to receive or not receive dapagliflozin. We assessed the change in KCCQ score from baseline to 3 and 12 months by using an ordinal logistic regression model. Additionally, we analyzed the effect of dapagliflozin on the composite of death or worsening HF by baseline KCCQ score. A total of 964 patients had baseline KCCQ scores (mean 39.5 ± 22.2). Patients in both arms of the study exhibited improvements in KCCQ score, without significant differences between groups in the change in KCCQ score at 3 or 12 months (3-month OR for improvement: 0.96; 95% CI: 0.72-1.26; P = 0.745; 12-month OR: 1.03; 95% CI: 0.83-1.27; P = 0.819). At 12 months, similar proportions of patients in the dapagliflozin and control groups showed clinically meaningful improvements, with 43.4% vs 45.4%, respectively, improving by >50 points. The clinical benefits of dapagliflozin after TAVI appeared to be similar across the full range of baseline KCCQ scores. TAVI was associated with a substantial improvement in KCCQ scores. However, the addition of dapagliflozin following the procedure did not confer an additional benefit in health status compared with standard care. (Dapagliflozin After Transcatheter Aortic Valve Implantation [DapaTAVI]; NCT04696185). eng NYHA functional class aortic stenosis dapagliflozin quality of life transcatheter aortic valve implantation (TAVI) Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. research article 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 URL https://repisalud.isciii.es/bitstreams/cb8b893d-73cf-4573-80e6-e1d4c0d1dde7/download File MD5 f14fb6a2e2df1f62bf14ee8fca78b88b 167623 application/pdf Effect of Dapagliflozin on Quality of Life_J Am Coll Cardiol_2025 .pdf